Allogene Therapeutics (ALLO) EBITDA (2018 - 2026)

Allogene Therapeutics has disclosed EBITDA across 9 years of filings, most recently posting -$43.1 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$43.1 million, up 27.75% year-over-year; the trailing twelve-month figure through Mar 2026 was -$174.0 million (up 30.78% YoY), and the FY2025 annual result was -$190.5 million, up 25.78% from the prior year.
• EBITDA came in at -$43.1 million for Q1 2026 at Allogene Therapeutics, down from -$38.8 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$38.8 million in Q4 2025 to a low of -$96.0 million in Q1 2023.
• The 5-year median for EBITDA is -$65.4 million (2024), against an average of -$68.0 million.
• Across the five-year window, EBITDA plunged 4424.39% in 2022 and jumped 37.08% in 2025, its largest moves.
• Allogene Therapeutics' EBITDA stood at -$94.2 million in 2022, then rose by 10.53% to -$84.3 million in 2023, then grew by 28.62% to -$60.2 million in 2024, then soared by 35.57% to -$38.8 million in 2025, then declined by 11.05% to -$43.1 million in 2026.
• The last three EBITDA figures came in at -$43.1 million (Q1 2026), -$38.8 million (Q4 2025), and -$41.1 million (Q3 2025), per Business Quant data.